Business
FINAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2021
FINAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2021.
About this update from Arecor Therapeutics Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 1310J\n Arecor Therapeutics PLC\n 25 April 2022\n \n \n \n \n Arecor Therapeutics plc\n \n \n (\"Arecor\", the \"Company\" or the \"Group\")\n \n \n \n \n \n FINAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2021\n \n \n \n \n \n Positive Phase I clinical trial for AT278 ultra-concentrated ultra-rapid acting insulin candidate for diabetes\n \n \n \n \n \n Five new technology partnership agreements\n \n \n \n \n \n Expansion of IP portfolio underpinning proprietary Arestat™ platform\n \n \n \n \n \n Successful £20 million AIM IPO\n \n \n \n \n \n \n Cambridge, UK, \n \n 25 April 2022: Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical company advancing today's therapies to enable healthier lives, today announces its final results for the year ended 31 December 2021.\n \n \n \n \n \n Sarah Howell, Chief Executive Officer of Arecor, said: \"\n \n After a year of significant progress in 2021, we are well positioned to continue to execute our strategy in 2022 and beyond as we develop enhanced therapeutic products that can truly transform patient care. As we look forward, I am excited about the opportunities ahead in 2022, especially within our proprietary pipeline with additional clinical data for AT247 expected later in the year following the excellent clinical results for the AT278 first-in-man study. We have a strong pipeline of opportunities ahead within our Specialty Hospital portfolio and I look forward to us continuing to build on our strong partnering performance.\"\n \n \n \n \n \n \n Operational Highlights (including post-period events):\n \n \n \n \n \n · \n AT247, an ultra-rapid acting insulin, advancing rapidly through clinical trials\n \n \n - US Phase I clinical trial initiated in early 2022, following FDA clearance of IND application\n \n \n · \n Positive Phase I clinical trial for AT278, an ultra-concentrated ultra-rapid acting insulin\n \n \n - Significantly early accelerated PK/PD profile compared to market leading comparator, NovoRapid®\n \n \n - Data to be presented at ATTD on 28 April 2022\n \n \n · \n Five new technology partnership agreements\n \n \n · \n Awarded £2.8 million Innovate UK grant to support Phase II development of AT247\n \n \n · \n Expansion of global patent portfo...